[HTML][HTML] Opportunities and challenges for human papillomavirus vaccination in cancer
R Roden, PL Stern - Nature Reviews Cancer, 2018 - nature.com
The discovery of genotype 16 as the prototype oncogenic human papillomavirus (HPV)
initiated a quarter century of laboratory and epidemiological studies that demonstrated their …
initiated a quarter century of laboratory and epidemiological studies that demonstrated their …
[HTML][HTML] Therapeutic vaccines for high-risk HPV-associated diseases
Cancer is the second leading cause of death worldwide, and it is estimated that Human
papillomavirus (HPV) related cancers account for 5% of all human cancers. Current HPV …
papillomavirus (HPV) related cancers account for 5% of all human cancers. Current HPV …
The use of both therapeutic and prophylactic vaccines in the therapy of papillomavirus disease
AR Garbuglia, D Lapa, C Sias… - Frontiers in …, 2020 - frontiersin.org
Human papillomavirus (HPV) is the most common sexually transmitted virus. The high-risk
HPV types (ie, HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59) are considered to be the …
HPV types (ie, HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59) are considered to be the …
Role of human papillomavirus (HPV) vaccination on HPV infection and recurrence of HPV related disease after local surgical treatment: systematic review and meta …
Objective To explore the efficacy of human papillomavirus (HPV) vaccination on the risk of
HPV infection and recurrent diseases related to HPV infection in individuals undergoing …
HPV infection and recurrent diseases related to HPV infection in individuals undergoing …
[HTML][HTML] Explanations for the high potency of HPV prophylactic vaccines
J Schiller, D Lowy - Vaccine, 2018 - Elsevier
HPV L1 virus-like particle (VLP) vaccines administered in a prime/boost series of three
injections over six months have demonstrated remarkable prophylactic efficacy in clinical …
injections over six months have demonstrated remarkable prophylactic efficacy in clinical …
SPERANZA project: HPV vaccination after treatment for CIN2+
A Ghelardi, F Parazzini, F Martella, A Pieralli, P Bay… - Gynecologic …, 2018 - Elsevier
Results From January 2013, all women diagnosed with a CIN2+ cervical lesion/stage IA1
cervical cancer treated with cervical conization in the Department of Obstetrics and …
cervical cancer treated with cervical conization in the Department of Obstetrics and …
[HTML][HTML] Incidence and mortality from cervical cancer and other malignancies after treatment of cervical intraepithelial neoplasia: a systematic review and meta …
Background Although local treatments for cervical intraepithelial neoplasia (CIN) are highly
effective, it has been reported that treated women remain at increased risk of cervical and …
effective, it has been reported that treated women remain at increased risk of cervical and …
Platforms, advances, and technical challenges in virus-like particles-based vaccines
R Gupta, K Arora, SS Roy, A Joseph… - Frontiers in …, 2023 - frontiersin.org
Viral infectious diseases threaten human health and global stability. Several vaccine
platforms, such as DNA, mRNA, recombinant viral vectors, and virus-like particle-based …
platforms, such as DNA, mRNA, recombinant viral vectors, and virus-like particle-based …
HPV vaccination and cancer prevention
A Athanasiou, S Bowden, M Paraskevaidi… - Best Practice & …, 2020 - Elsevier
Prophylactic vaccines have been found to be highly effective in preventing infection and pre-
invasive and invasive cervical, vulvovaginal and anal disease caused by the vaccine types …
invasive and invasive cervical, vulvovaginal and anal disease caused by the vaccine types …
Adjuvant HPV vaccination to prevent recurrent cervical dysplasia after surgical treatment: a meta-analysis
Objective: The aim of this meta-analysis was to discuss evidence supporting the efficacy of
adjuvant human papillomavirus (HPV) vaccination in reducing the risk of recurrent cervical …
adjuvant human papillomavirus (HPV) vaccination in reducing the risk of recurrent cervical …